Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of edoxaban in geriatric patients with atrial fibrillation
2022-004136-26Phase 4Completed
- Sponsor
- KU Leuven
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of edoxaban in Atrial fibrillation (AFib), sponsored by KU Leuven. Primary endpoint: Primary pharmacokinetic metrics of edoxaban. Started Jan 2023; status: completed.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2022-004136-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004136-26.